Immix Biopharma (IMMX) Short Interest Ratio & Short Volume

Short interest is the volume of Immix Biopharma shares that have been sold short but have not yet been closed out or covered. As of November 30th, traders have sold 470,700 shares of IMMX short. 2.87% of Immix Biopharma's shares are currently sold short. Learn More on Immix Biopharma's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IMMX shares currently have a short interest ratio of 3.0. Learn More on Immix Biopharma's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.87% of Immix Biopharma's floating shares are currently sold short.

Immix Biopharma saw a increase in short interest during the month of November. As of November 30th, there was short interest totaling 470,700 shares, an increase of 17.5% from the previous total of 400,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Immix Biopharma currently has issued a total of 27,508,000 shares. Some of Immix Biopharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Immix Biopharma currently has a public float of 16,410,000 shares.

2.87% of Immix Biopharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Immix Biopharma: SOPHiA GENETICS SA (0.06%), Biomea Fusion, Inc. (31.36%), XBiotech Inc. (4.07%), Inhibrx, Inc. (11.02%), Cardiff Oncology, Inc. (16.00%), LifeVantage Co. (2.00%), Silence Therapeutics plc (2.35%), Compass Therapeutics, Inc. (1.70%), MacroGenics, Inc. (9.00%), Candel Therapeutics, Inc. (10.86%),

As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks.

Short selling IMMX is an investing strategy that aims to generate trading profit from Immix Biopharma as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Immix Biopharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IMMX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IMMX, twice per month. The most recent reporting period available is November, 30 2024.